Omilancor

Omilancor (BT-11) is an orally active lanthionine synthetase cyclase-like receptor 2 (LANCL2) activator. Omilancor can be used for the study of psoriasis, inflammatory bowel disease (IBD), and Crohn's disease (CD) [1][2][3].

Product Specifications

CAS Number

[1912399-75-7]

Product Name Alternative

BT-11

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/BT-11.html

Purity

98.44

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C(C2=NC(C3=NC4=CC=CC=C4N3)=CC=C2)=O)CC1)C5=NC(C6=NC7=CC=CC=C7N6)=CC=C5

Molecular Formula

C30H24N8O2

Molecular Weight

528.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Carbo A, et al. An N, N-Bis (benzimidazolylpicolinoyl) piperazine (BT-11) : A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem. 2016 Nov 23;59 (22) :10113-10126.|[2]Bissel P, et al. Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. Int J Toxicol. 2016 Sep;35 (5) :521-9.|[3]Tubau-Juni N, et al. First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis. Sci Rep. 2021 Oct 6;11 (1) :19827.